Similar Search Results

Collaboration, Stars, and the Changing Organization of Science : Evidence from Evolutionary Biology

Agrawal, Ajay - 2013

We report a puzzling pair of facts concerning the organization of science. The concentration of research output is declining at the department level but increasing at the individual level. For example, in evolutionary biology, over the period 1980 to 2000, the fraction of citation-weighted...

Persistent link: https://www.econbiz.de/10012459010

Tracing the Linkages Between Scientific Research and Energy Innovations : A Comparison of Clean and Dirty Technologies

Perrons, Robert K. - 2020

development of new energy technologies (Popp, 2017). Energy innovation tends to consist of a series of partially overlapping …

Persistent link: https://www.econbiz.de/10012481080

Expected Profits and The Scientific Novelty of Innovation

Dranove, David - 2020

Innovation policy involves trading off monopoly output and pricing in the short run in exchange for incentives for …

Persistent link: https://www.econbiz.de/10012481677

The Impact of Regulation on Innovation

Aghion, Philippe; Bergeaud, Antonin; Van Reenen, John - National Bureau of Economic Research - 2021

Does regulation affect the pace and nature of innovation and if so, by how much? We build a tractable and quantifiable … sharp reduction in the firm's innovation response to exogenous demand shocks for firms just below the regulatory threshold …. We then quantitatively fit the parameters of the model to the data, finding that innovation at the macro level is about 5 …

Persistent link: https://www.econbiz.de/10012482599

Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003

Lichtenberg, Frank R. - 2008

Countries with larger increases in the share of cardiovascular drug doses that contained post-1990 or post-1995 ingredients had smaller increases in the cardiovascular disease hospital discharge rate, controlling for the quantity of cardiovascular medications consumed per person, the use of...

Persistent link: https://www.econbiz.de/10012464639

Innovation, Diffusion, and Trade

Eaton, Jonathan - 2006

We explore the determinants of research specialization across countries and its consequences for relative wages. Using a dynamic Ricardian model we examine the effects of faster international technology diffusion and lower trade barriers on the incentive to innovate. In the absence of any...

Persistent link: https://www.econbiz.de/10012466280

Is Public R&D a Complement or Substitute for Private R&D? A Review of the Econometric Evidence

David, Paul A. - 1999

Is public R&D spending complementary and thus "additional" to private R&D spending, or does it substitute for and tend to "crowd out" private R&D? Conflicting answers are given to this question. We survey the body of available economectric evidence accumulated over the past 35 years. A framework...

Persistent link: https://www.econbiz.de/10012471411

International R&D Spillovers : A Re-Examination

Lichtenberg, Frank - 1996

Coe and Helpman(1995) have measured the extent to which technology spills over between industrialized countries through the particular channel of trade flows. This paper re-examines two particular features of their study. First, we suggest that their functional form of how foreign R&D affects...

Persistent link: https://www.econbiz.de/10012473174

International R&D Spillovers

Coe, David T. - 1993

Investment in research and development (R&D) affects a country's total factor productivity. Recently new theories of economic growth have emphasized this link and have also identified a number of channels through which a country's R&D affects total factor productivity of its trade partners....

Persistent link: https://www.econbiz.de/10012474506

The Role of Assets In Place : Loss of Market Exclusivity and Investment

Higgins, Matthew J. - 2020

We utilize a novel identification strategy to analyze the impact of assets in place on firms' decisions for future projects. We exploit the context in the pharmaceutical industry, where the loss of market exclusivity for a branded drug can be used to separate the impact of cash flows generated...

Persistent link: https://www.econbiz.de/10012481442

1
2
3
4
5
6
7
8
9
10
Next
Last